Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation-Reference-Cited by-同舟云学术

Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation

Published:2023-10 Issue: Volume:177 Page:132-141
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Toboni Michael D.,Wu Sharon,Farrell Alex,Xiu Joanne,Ribeiro Jennifer R.,Oberley Matthew J.,Arend Rebecca,Erickson Britt K.,Herzog Thomas J.,Thaker Premal H.,Powell Matthew A.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference45 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

2. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis;Sohaib;Clin. Radiol.,2007

3. SEER Cancer Statistics Review, 1975–2016,2019

4. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study;Keys;Gynecol. Oncol.,2004

5. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma;Creutzberg;Lancet.,2000

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study;Nature Communications;2024-09-03

2. Treatment options in the advanced and recurrent setting for endometrial cancer: an update;Expert Review of Anticancer Therapy;2024-06-24

3. Insights into MLH1 Methylation in Endometrial Adenocarcinoma through Pyrosequencing Analysis: A Retrospective Observational Study;Cancers;2024-06-01

4. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers;Cancer;2024-02-29

5. Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations;Clinical Cancer Research;2024-02-13